Drug news
Daclatasvir (BMS) and TME 435(Tibotec) combination for Phase II for Hepatitis C
BMS will collaborate with Tibotec, a Johnson & Johnson company, to investigate the combination of oral drug daclatasvir, a NS5A replication complex inhibitor, plus TMC435 a once a day oral NS 3/4a protease inhibitor for the treatment of chronic Hepatitis C genotype 1. The combination will enter a Phase II study early next year to investigate the potential for sustained viral response 12 and 24 weeks post-treatment in patients with HCV genotype 1. Both drugs are in Phase III development.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.